ADO09 , a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G , lowers postprandial blood glucose versus insulin lispro in type 1 diabetes

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

Physico-chemical properties of co-formulated fast-acting insulin with pramlintide

(2018) Dayana Cabral da Silva et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study

(2018) Matthew C. Riddle et al.   DIABETES CARE

Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis

(2017) Yong-Chao Qiao et al.   Oncotarget

Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes

(2016) Ling Hinshaw et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes

(2015) M. C. Riddle et al.   DIABETES OBESITY & METABOLISM

In Silico Design of Optimal Ratio for Co-Administration of Pramlintide and Insulin in Type 1 Diabetes

(2013) Francesco Micheletto et al.   Diabetes Technology & Therapeutics

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

(2012) P. Lucidi et al.   DIABETES CARE

Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus

(2010) N. J. Lee et al.   ANNALS OF FAMILY MEDICINE

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites

(2010) Mark R. Sommerfeld et al.   PLoS One